$1.88
+0.27%
N/A+$0.01
헬스케어
생명공학
NASDAQ
활발히 거래 중
Lantern Pharma Inc.는 인공지능, 머신러닝, 포괄적인 유전체 데이터 분석의 전략적 적용을 통해 약물 개발을 혁신하는 데 전념하는 임상 단계 생명공학 기업입니다. 이들의 ...
Lantern Pharma Inc.는 인공지능, 머신러닝, 포괄적인 유전체 데이터 분석의 전략적 적용을 통해 약물 개발을 혁신하는 데 전념하는 임상 단계 생명공학 기업입니다. 이들의 ...
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| May 12, 2026 | Schalop Lee Troy | director | Common stock purchase warrant (Right to Buy) | D | 48,544 | $2.27 |
| May 12, 2026 | Schalop Lee Troy | director | Common stock, $0.001 par value | A | 48,544 | $2.06 |
| May 12, 2026 | KEYSER D JEFFREY | director | Common stock, $0.001 par value | A | 48,544 | $2.06 |
| May 12, 2026 | KEYSER D JEFFREY | director | Common stock purchase warrant (Right to Buy) | D | 48,544 | $2.27 |
| Jan 9, 2026 | KEYSER D JEFFREY | director | Stock Option (Right to Buy) | A | 28,844 | $3.49 |
매수/매도 주식 수와 종가 추세(공통 일간 가격 소스)
X축: 주식 수, 총 주식 수 내림차순
X축: 건수, A+D 건수 내림차순
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 | 금액 |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | Schalop Lee Troy | director | Common stock purchase warrant (Right to Buy) | D | 48,544 | $2.27 | $110,194.88 |
| May 12, 2026 | Schalop Lee Troy | director | Common stock, $0.001 par value | A | 48,544 | $2.06 | $100,000.64 |
| May 12, 2026 | KEYSER D JEFFREY | director | Common stock, $0.001 par value | A | 48,544 | $2.06 | $100,000.64 |
| May 12, 2026 | KEYSER D JEFFREY | director | Common stock purchase warrant (Right to Buy) | D | 48,544 | $2.27 | $110,194.88 |
| Jan 9, 2026 | KEYSER D JEFFREY | director | Stock Option (Right to Buy) | A | 28,844 | $3.49 | $100,665.56 |
| Jan 9, 2026 | KEYSER D JEFFREY | director | Stock Option (Right to Buy) | A | 25,000 | $3.49 | $87,250.00 |
| Jan 9, 2026 | Maccecchini Maria-Luisa | director | Stock Option (Right to Buy) | A | 25,000 | $3.49 | $87,250.00 |
| Jan 9, 2026 | Maccecchini Maria-Luisa | director | Stock Option (Right to Buy) | A | 21,152 | $3.49 | $73,820.48 |
| Jan 9, 2026 | Chandru Vijay | director | Stock Option (Right to Buy) | A | 25,000 | $3.49 | $87,250.00 |
| Jan 9, 2026 | Chandru Vijay | director | Stock Option (Right to Buy) | A | 17,307 | $3.49 | $60,401.43 |